Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems
Other posts you may like
Join us during SPS annual meeting in Barcelona, Spain for our sponsored presentation with Amgen.
Discover how emka helps you to comply with regulatory guidance
September 28- October 02, 2019 Madrid, SPAIN Booth # V13
Discover our new myograph module and perfusion system!